Hypervitaminemia B12: A Biological Marker yet to be Known

Zulfiqar Abrar-Ahmad*1 and Andres Emmanuel2
1Department of Geriatrics, University Hospital of Rouen, France
2Department of Internal Medicine, University Hospital of Strasbourg, France
Submission: October 29, 2018; Published: November 16, 2018
*Corresponding author: Zulfiqar Abrar-Ahmad, M.D.MSc, Department of Geriatrics, Saint-Julien Hospital, University Hospital of Rouen, 76141 Le Petit Quevilly, France

Introduction
A high serum level of vitamin B12 (or cobalamin), also called hypervitaminemia B12 is a biological abnormality, yet one that is significantly underestimated. To date, no consensus on the management of this anomaly exists. According to the literature, high levels of vitamin B12 are associated or linked with a range of conditions, the majority of which are serious, with a systematic inquiry being decisive for prognosis following the discovery of a high serum cobalamin level [1-3]. In clinical practice, the frequent occurrence of vitamin B12 deficiency, particularly in elderly patients, justifies systematic dosing with vitamin B12. A high serum cobalamin level, which appears to be even more common than vitamin B12 deficiency [3,4], is therefore often discovered only fortuitously. Recent works have proposed that systematic etiological research as early etiological management is decisive for treatment outcomes [2,5,6].

Metabolism of Vitamin B12 and Physiological Basis
Vitamin B12 (Cobalamin) is an essential micronutrient that plays a fundamental role in cell division and one-carbon metabolism. Vitamin B12 is absorbed in the small intestine where the vitamin B12-intrinsic factor (IF) complex binds to a receptor, which is called cubam[7]. The source of vitamin B12 is exogenous, predominantly of animal origin. Many foods are a natural source of vitamin B12, because of bacterial symbiosis. It has been suggested that the current recommended daily intake for vitamin B12 may be inadequate to ensure genomic stability and that a vitamin B12 intake of 7µg/day, needed for a plasma level of 400 pg/ml, would be more appropriate [8]. After ingestion of vitamin B12, its dissociation from its carrier proteins by gastric acid and pancreatic secretions is an essential prerequisite for the binding of vitamin B12 to the IF secreted by gastric parietal cells [9]. The vitamin B12-IF complex reaches the terminal ileum, where absorption of vitamin B12 occurs. The transport of vitamin B12 in the blood, as well as its tissue and hepatic uptake, require the presence of transcobalamin (TCB) [10].

Serum B12 is bound to both transcobalamin (TCB) and haptocorrin (HC). These partly saturated (holo) and partly unsaturated (apo) with B12 proteins circulate in the blood. TCB I and TCB III ensure the binding of 80% of circulating vitamin B12; however, TCB II plays the important role in the key processes of tissue and hepatic uptake of vitamin B12. Holotranscobalamin II is composed of vitamin B12 attached to TCB II, and it represents the biologically active fraction that can be delivered into all DNA synthesizing cells. Liver storage of vitamin B12 is mediated by endothelial cells, hepatocytes being naturally devoid of TCB II receptors [1]. TCB saturated with B12 (holo-TCB) constitutes 6 to 20% of endogenous circulating B12. In contrast, HC binds ~80–94% of the endogenous plasma B12 (holo-HC), and is largely saturated with B12 or analogs [11].

Hypervitaminemia B12: Prognostic Marker?
An association between hypervitaminosis B12 and solid neoplasms was demonstrated in a study of vitamin B12 and haptocorrin levels in a population of 139 individuals with malignant disease [12]. The main relevant cancers are hepatocellular carcinoma (HCC) and secondary liver tumors, breast cancer, colon cancer, stomach cancer, and pancreatic tumors [1]. Pathophysiological, in solid tumors, hypervitaminosis B12 is mainly linked to excessive synthesis of transcobalamins by the tumor or high haptocorrin levels due to leukocytosis reaction [1]. Hypervitaminosis B12 has also been described as a potential tumor marker of poor prognosis [13]. A previous study [14] found strong predictive value for mortality for hypervitaminosis B12 in individuals with cancer receiving palliative care. A study of the prognosis of people with cancer and hypervitaminosis B12 found a strong association between hypervitaminosis B12 and poor prognosis, with a median survival of approximately 1 month.

Metastases were also more frequent in this subgroup [15]. Likewise, another study found greater mortality associated with high levels of vitamin B12 in a series of 1,570 individuals
aged 65 and older admitted to a geriatric ward [16]. It has been suggested that vitamin B12 levels be used as a tool in investigatory and therapeutic decision-making, especially in severely ill individuals or those with chronic disease [15]. Prognostic value has been attributed to vitamin B12 in cancer; and an index, the vitamin B12/CRP Index (BCI), has been developed that has a high predictive value for mortality in cancer in palliative care (P < .001) [15]. A BCI greater than 40,000 was associated with 90% mortality at 3 months. The highest rate was associated with the highest mortality [15]. A study of 329 individuals with advanced cancer confirmed these findings, with 29-day median survival in those with a BCI greater than 40,000 (P < .01) [17].

The BCI of the woman described above was estimated at 52,200. The BCI should be considered as an additional prognostic indicator, alongside the PPS [18] and the PPI [19]. The PPI consists of a weighted scale assessing five clinical variables (performance status, oral intake, edema, dyspnea at rest, delirium) [19]. These two instruments do not include clinician estimates as an independent prognostic factor. Moreover, BCI does not rely on subjective estimates of symptom severity or clinician estimates of survival.

**Conclusion**

Further exploratory studies are warranted to explore serum vitamin B12 and the BCI as a tool in investigatory and therapeutic decision-making and to develop new prognostic scales for elderly adults.

**Conflict of Interest**

The author declares no conflict of interest.

**References**


How to cite this article: Zulfiqar Abrar-Ahmad, Andres Emmanuel. Hypervitaminemia B12: A Biological Marker yet to be Known. Palliat Med Care Int J. 2018; 1(1): 555553. DOI: 10.19080/PMCIJ.2018.01.555553

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php